Get the Stockscreener App
0.2759
8.97%
-0.0272
Relmada Therapeutics Inc stock is traded at $0.2759, with a volume of 353.81K.
It is down -8.97% in the last 24 hours and up +8.20% over the past month.
See More
Previous Close:
$0.3031
Open:
$0.294
24h Volume:
353.81K
Relative Volume:
0.35
Market Cap:
$9.16M
Revenue:
-
Net Income/Loss:
$-98.79M
P/E Ratio:
-0.0844
EPS:
-3.27
Net Cash Flow:
$-51.66M
1W Performance:
-7.42%
1M Performance:
+8.20%
6M Performance:
-91.59%
1Y Performance:
-94.14%
1-Day Range:
$0.2759
$0.3259
1-Week Range:
$0.26
$0.3259
52-Week Range:
$0.2404
$5.09
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Name
Relmada Therapeutics Inc
Sector
Industry
Phone
646 876 3459
Address
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Compare RLMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
20.64 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1672 | 352.85M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
MOBBW
Mobilicom Limited Warrants
|
0.34 | 278.60M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
11.05 | 144.42M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
3.20 | 137.80M | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-17-24 | Upgrade | Jefferies | Hold → Buy |
| Jun-05-24 | Downgrade | Goldman | Neutral → Sell |
| Oct-14-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-14-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-14-22 | Downgrade | Truist | Buy → Hold |
| Oct-13-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-18-21 | Initiated | Mizuho | Buy |
| May-20-21 | Resumed | Goldman | Buy |
| Oct-28-20 | Downgrade | Goldman | Buy → Neutral |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-04-20 | Initiated | SunTrust | Buy |
| Apr-21-20 | Initiated | Goldman | Buy |
| Jan-27-20 | Initiated | Jefferies | Buy |
| Jan-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-16-19 | Initiated | Guggenheim | Buy |
View All
Relmada Therapeutics Inc Stock (RLMD) Latest News
Relmada outlines plans for NDV-01 Phase 2 results presentation and sepranolone development - MSN
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2024 Earnings Call Transcript - Insider Monkey
Relmada Therapeutics: Strategic Acquisitions and Pipeline Progress - TipRanks
Relmada Therapeutics pivots from psilocybin to cancer, neurological disorders - Green Market Report
Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights: Strategic Acquisitions and ... - Yahoo Finance
Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights - GuruFocus.com
Relmada Therapeutics Reports 2024 Financial Results and Strategic Progress - TipRanks
Earnings call transcript: Relmada Therapeutics Q4 2024 sees improved EPS By Investing.com - Investing.com South Africa
Earnings call transcript: Relmada Therapeutics Q4 2024 sees improved EPS - Investing.com India
RELMADA THERAPEUTICS Earnings Results: $RLMD Reports Quarterly Earnings - Nasdaq
Relmada Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update - The Manila Times
Relmada Cuts Losses by 25%: Key Pipeline Programs Hit Critical Phase in 2025 - Stock Titan
Relmada Therapeutics Inc -On March 24, Enters Exclusive License Agreement With Trigone PharmaSEC Filing - MarketScreener
Insights Ahead: Relmada Therapeutics's Quarterly Earnings - Benzinga
Mizuho maintains Relmada stock neutral with $1.00 target By Investing.com - Investing.com Canada
Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025 - Quantisnow
Mizuho maintains Relmada stock neutral with $1.00 target - Investing.com India
Mizuho Reiterates Neutral Rating on Relmada Therapeutics Inc (RLMD) - StreetInsider.com
Q4 Earnings Alert: Relmada Therapeutics Reveals Key Financial Results Date - Stock Titan
Relmada secures exclusive license for potential bladder cancer therapy By Investing.com - Investing.com South Africa
Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd. - Quantisnow
Relmada secures exclusive license for potential bladder cancer therapy - Investing.com India
Relmada Therapeutics Announces Exclusive Licensing Agreement for NDV-01, a Novel Intravesical Therapy for Non-Muscle Invasive Bladder Cancer - Nasdaq
Relmada Therapeutics (RLMD) Licenses NDV-01 from Trigone Pharma - StreetInsider.com
Game-Changing Cancer Drug: Relmada's New Treatment Lasts 10 Days vs Hours - Stock Titan
RELMADA THERAPEUTICS Earnings Preview: Recent $RLMD Insider Trading, Hedge Fund Activity, and More - Nasdaq
Relmada Therapeutics Inc expected to post a loss of 70 cents a shareEarnings Preview - TradingView
Relmada Therapeutics (RLMD) Projected to Post Earnings on Tuesday - Defense World
Relmada seeking strategic options, stock climbs 5% - MSN
RELMADA THERAPEUTICS, INC. INVESTIGATION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Relmada Therapeutics, Inc. - ACCESS Newswire
Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight - GlobeNewswire Inc.
RLMD stock touches 52-week low at $0.28 amid market challenges - Investing.com Australia
RLMD stock touches 52-week low at $0.28 amid market challenges By Investing.com - Investing.com South Africa
A significant driver of top-line growth: Relmada Therapeutics Inc (RLMD) - SETE News
Relmada acquires new Tourette syndrome treatment asset - MSN
Relmada Therapeutics Inc [RLMD] Investment Guide: What You Need to Know - Knox Daily
RLMD stock’s current quarter earnings estimates: What analysts predict? - US Post News
Closing Strong: Relmada Therapeutics Inc (RLMD) Ends at 0.31, Down -9.62 from Last Close - The Dwinnex
Relmada Therapeutics Inc’s Shares Reel: -90.69% Quarterly Revenue Decline Amid 9.33M Market Cap - The InvestChronicle
A company insider recently bought 51,407 shares of Relmada Therapeutics Inc [RLMD]. Should You Buy? - Knox Daily
Mizuho maintains Neutral on Relmada stock, sees deal potential - MSN
The Tourette’s Deal That Came Too Late To Save Sweden’s Asarina - Insights
Relmada in-licenses Tourette syndrome drug from Asarina - The Pharma Letter
Take off with Relmada Therapeutics Inc (RLMD): Get ready for trading - SETE News
Relmada acquires Tourette’s therapy rights from Asarina - Yahoo Finance
Lipella Pharmaceuticals Inc [LIPO] Revenue clocked in at $0.48 million, up 52.46% YTD: What’s Next? - The DBT News
Relmada acquires new Tourette syndrome treatment asset By Investing.com - Investing.com Nigeria
Mizuho maintains Neutral on Relmada stock, sees deal potential By Investing.com - Investing.com Australia
Relmada Therapeutics Acquires Sepranolone From Asarina Pharma For Potential TS Treatment - Nasdaq
Relmada Therapeutics Inc Stock (RLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.23%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):